PRELUDE THERAPEUTICS INC (PRLD)
US74065P1012 - Common Stock
ChartMill assigns a Buy % Consensus number of 49% to PRLD. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 5.92. This target is 54.46% above the current price.
PRLD was analyzed by 9 analysts. The buy percentage consensus is at 49. So analysts seem to be rather neutral about PRLD.
In the previous month the buy percentage consensus was at a similar level.
PRLD was analyzed by 9 analysts. More opinions would make the average more meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2024-03-13 | JMP Securities | Initiate | Market Outperform |
| 2024-02-20 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2023-12-19 | Morgan Stanley | Downgrade | Equal-Weight -> Underweight |
| 2023-11-07 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-10-19 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-08-17 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-08-04 | Barclays | Maintains | Equal-Weight -> Equal-Weight |
| 2023-08-04 | Morgan Stanley | Reiterate | Equal-Weight -> Equal-Weight |
| 2023-03-17 | HC Wainwright & Co. | Maintains | Buy |
| 2022-11-21 | B of A Securities | Downgrade | Neutral -> Underperform |
| 2022-11-17 | HC Wainwright & Co. | Maintains | Buy |
| 2022-11-15 | Morgan Stanley | Maintains | Equal-Weight |
| 2022-09-09 | Morgan Stanley | Downgrade | Overweight -> Equal-Weight |
| 2022-07-29 | Jefferies | Initiate | Buy |
| 2022-05-12 | HC Wainwright & Co. | Maintains | Buy |
| 2022-02-28 | Barclays | Downgrade | Overweight -> Equal-Weight |
| 2021-11-17 | Barclays | Maintains | Overweight |
| 2021-10-11 | Morgan Stanley | Upgrade | Equal-Weight -> Overweight |
| 2021-10-08 | Barclays | Maintains | Overweight |
| 2021-07-27 | B of A Securities | Upgrade | Neutral -> Buy |
| 2021-04-26 | HC Wainwright & Co. | Initiate | Buy |
| 2021-03-17 | Morgan Stanley | Maintains | Equal-Weight |